期刊名称：CURRENT TREATMENT OPTIONS IN ONCOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Current Treatment Options in Oncology was developed out of the recognition that it is increasingly difficult for specialists to keep up to date with the expanding number of treatment options published in their subject. Current Treatment Options in Oncology aims to help the reader by providing a systematic manner:
1 the views of experts on current treatment options in oncologic medicine in a clear and readable format, and
2 selections annotated by experts of the most interesting papers from the great wealth of original publications.
Current Treatment Options in Oncology is indexed by Index Medicus and MEDLINE.
Related subjects » Oncology & Hematology
Abstracted/Indexed in:
Academic OneFile, Current Contents/Clinical Medicine, EMBASE, Gale, Google Scholar, Health Reference Center Academic, IBIDS, Journal Citation Reports/Science Edition, OCLC, PubMed/Medline, Science Citation Index Expanded (SciSearch), SCOPUS, Summon by Serial Solutions
Instructions to Authors
Instructions for Authors
Current Treatment Options in Oncology
Aims and Scope
Current Treatment Options in Oncology is a bimonthly compilation of papers by leading experts discussing the latest therapeutic options in the field of oncology. The publication highlights new techniques, drugs, procedures, and important advances in treatment. Top experts systematically review the latest treatment options for oncology from all available sources, and offer their own personal approach to the management of common problems.
The publication emphasizes the recent literature, current society guidelines, and personal and/or institutional experience. Topics not directly related to treatment, such as basic science and diagnoses, should be kept to a minimum. Your paper should include 1) what treatment options are available, 2) a comparison of these options, and 3) a clearly defined Opinion Statement as to the best course of treatment, using your personal or institutional experience.
Some areas that must be covered include:
• Treatment aims
• Pharmaceutical options: available drugs,
pharmacodynamics/pharmacokinetics, drug
interactions, side effects, cost effectiveness,
etc.
• Procedures
• Prognosis
• Follow-up management
• Diet and lifestyle factors
• Emerging therapies
Illustrations, photographs, and tables may be used judiciously to supplement the text.
General
Authors are to prepare an original paper that discusses interesting developments and important advances related to their topic, highlighting their own experiences where relevant. Please emphasize new clinical applications, new techniques, drugs, procedures, and important advances in treatment. Describe your own approaches and experiences where relevant and report critically on current debates in the field. Topics not directly related to treatment, such as basic science and diagnoses, should be kept to a minimum. Papers should be 3000-4000 words.
Manuscript Submission
- Legal Requirements
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities - tacitly or explicitly - at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
- Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
- How to Submit
Manuscript submission is by invitation of the Section Editor only.
Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please connect directly to the site and upload all of your manuscript files following the instructions given on the screen.
Manuscript Preparation
- Title Page
The title page should include:
- The name(s) of the author(s)
- A concise and informative title
- The affiliation(s) and address(es) of the
author(s)
- The e-mail address, telephone and fax
numbers of the corresponding author
- Opinion Statement
An Opinion Statement should open your paper. The Opinion Statement should be a summary of your personal opinion regarding the best treatment option(s). Style-wise, Opinion Statements should be treated as Abstracts (no figure, table, or reference call outs). See the sample article (if you did not receive a copy of the sample, please contact our office).
- Text Formatting
For submission in Word
• Use a normal, plain font (e.g., 10-point Times
Roman) for text.
• Use italics for emphasis.
• Use the automatic page numbering function to
number the pages.
• Do not use field functions.
• Use tab stops or other commands for indents,
not the space bar.
• Use the table function, not spreadsheets, to
make tables.
• Use the equation editor or MathType for
equations.
Note: If you use Word 2007, do not create the
equations with the default equation editor but
use MathType instead.
• Save your file in two formats: doc and PDF (a
single file including text, tables and figures).
Make sure that all fonts are embedded in the
PDF.
- Abbreviations and Acronyms
Abbreviations should be defined at first mention and used consistently thereafter.
- Terminology
Generic names of drugs and pesticides are preferred; if trade names are used, the generic name should be given at first mention.
- Footnotes
Footnotes on the title page are not given reference symbols. Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data).
- Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full.
- References
Contributors are asked to supply a list of references as described below:
Reference List at End of Text
No more than 60 modern references (1999–present).
Please limit their use to support data or statements made in the article. Inclusion of historical references is not encouraged.
List only references to which you have referred in the text.
This list should be numbered consecutively in the order in which they are cited in the text.
They should be assigned Arabic numerals, which should be given in brackets when they appear in the text. For example:
Hillman et al. [17] discussed cost and quality effects
of alternative treatments for infectious diseases.
The references listed at the end of the article should include the names of all authors, full title, journal name, year, volume, and page numbers. If there are five or more authors, only the first three authors should be listed, then followed by “et al.” Journal names should be abbreviated as in Index Medicus (if you do not know the correct abbreviation, give the journal name in full).
For example:
17. Hillman AL, Bloom BS, Fendrick M, et al.:
Cost and quality effects of alternative treatments for
infectious disease. Arch Intern Invest 1992,
152:1467–1472.
Web sites are acceptable as references, including both those associated with print journals and those that appear only on the Internet. Most importantly, please include the date of access and full name of web site and web site sponsoring organization.
For example:
1. Original website
Health Care Financing Administration: 1996 statistics at a glance. http:/www.hefa.gov/stats/stathili.htm. Accessed December 2, 2000.
2. Serial publication that also exists on the Web:
Jones CD: Preliminary results with tamoxifen in new application [abstract]. Proc ASCO 2000, 19:678. http://www.asco.org/
Key References
Authors are asked to choose at least 2 to 3 recent (1999–present) references from the main list (described above) that they regard as essential reading. Each key reference should be bulleted and also have a brief annotation (1 to 2 sentences) describing its significance. Annotated references that are of some special interest receive one bullet. Those that are of outstanding interest receive two bullets.
- Miscellaneous Content Issues
If you have a question regarding content, you may contact the in-house editor, who will direct the question to the Section Editor, or you may contact the Section Editor directly.
The in-house editorial staff can supply you with the phone/fax numbers.
You are welcome to work with a co-author if you prefer.
- Illustrations
Current Treatment Options in Oncology allows supplemental illustrations only when necessary to explicate the concepts presented. We suggest a maximum of 1 or 2 figures and/or 2 or 3 tables per article.
FIGURES
•All figures are to be numbered using Arabic numerals.
•Figure parts should be denoted by lowercase letters.
•Figures should always be cited in text in consecutive numerical order.
•For each figure, please supply a figure caption.
•Make sure to identify all elements found in the figure in the caption.
•Identify any previously published material by giving the original source in the form of a reference at the end of the caption.
•For more information about preparing your illustrations, please follow the hyperlink to the artwork instructions on the right.
TABLES
•All tables are to be numbered using Arabic numerals.
•Tables should always be cited in text in consecutive numerical order.
•For each table, please supply a table heading. The table title should explain clearly and concisely the components of the table.
•Identify any previously published material by giving the original source in the form of a reference at the end of the table heading.
•Footnotes to tables should be indicated by superscript lowercase letters (or asterisks for significance values and other statistical data) and included beneath the table body.
- ESM
If Electronic supplementary material (ESM) is submitted, it will be published as received from the author in the online version only.
ESM may consist of
• information that cannot be printed: animations,
video clips, sound recordings
• information that is more convenient in
electronic form: sequences, spectral data, etc.
• large original data, e.g. additional tables,
illustrations, etc.
• If supplying any ESM, the text must make
specific mention of the material as a citation,
similar to that of figures and tables (e.g., ". . .
as shown in Animation 3.").
• For details on formats and other information,
please follow the hyperlink to the specific
instructions for electronic supplementary
material on the right.
- If corrections or alterations are necessary, the Section Editor or in-house Editor will contact you with appropriate instructions.
After Acceptance
During the production phase the following issues have to be clarified:
- Open Choice
Open Choice In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer now provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer's online platform SpringerLink. We regret that Springer Open Choice cannot be ordered for published articles. Open Choice does not apply to Society Journals.
Springer Open Choice [http://springer.com/openchoice]
- Copyright
Copyright transfer Authors will be asked to transfer copyright of the article to the Publisher. This will ensure the widest possible protection and dissemination of information under copyright laws. Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, they agree to the Springer Open Choice Licence.
- Offprints
Free and/or additional offprints can be ordered by the corresponding author.
25 offprints of each contribution are supplied free of charge to the corresponding author.
- Color in Print
Online publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a contribution towards the extra costs.
- Online First
The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.
- Proofreading
The purpose of the proof is to check for typesetting errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor. After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.
Editorial Board
EDITOR-IN-CHIEF:
David S. Ettinger, The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD, USA
ASSOCIATE EDITOR:
J. Gordon McVie, European Institute of Oncology, Milan, Italy
EDITORIAL BOARD:
Al Benson, Chicago, IL; Terry Day, Charleston, SC; Glenn J. Lesser, Winston-Salem, NC; Stuart M. Lichtman, Commack, NY; Joseph Mirro, Milwauke, WI; Robert J. Morgan, Duarte, CA; Harvey Pass, New York, NY; Andrew J. Stephenson, Cleveland, OH; Heather Wakelee, Stanford, CA
|
